Published in J Immunol Methods on July 01, 2004
Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol (2011) 2.41
By-passing in vitro screening--next generation sequencing technologies applied to antibody display and in silico candidate selection. Nucleic Acids Res (2010) 1.87
Engineering of recombinant crystallization chaperones. Curr Opin Struct Biol (2009) 1.53
Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods Mol Biol (2009) 1.32
A new generation of protein display scaffolds for molecular recognition. Protein Sci (2006) 1.29
Libraries against libraries for combinatorial selection of replicating antigen-antibody pairs. Proc Natl Acad Sci U S A (2009) 1.24
Toward chaperone-assisted crystallography: protein engineering enhancement of crystal packing and X-ray phasing capabilities of a camelid single-domain antibody (VHH) scaffold. Protein Sci (2008) 1.20
Phage Therapy - Everything Old is New Again. Can J Infect Dis Med Microbiol (2006) 1.17
Creating protein affinity reagents by combining peptide ligands on synthetic DNA scaffolds. J Am Chem Soc (2009) 1.15
Development and characterization of novel photosensitizer : scFv conjugates for use in photodynamic therapy of cancer. Immunology (2007) 1.08
Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol (2007) 1.07
Antibody-based sensors: principles, problems and potential for detection of pathogens and associated toxins. Sensors (Basel) (2009) 1.07
Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel (2010) 1.07
On the influence of vector design on antibody phage display. J Biotechnol (2006) 1.07
Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. AAPS J (2012) 1.04
In vitro selection of Jun-associated proteins using mRNA display. Nucleic Acids Res (2004) 1.00
Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Protein Eng Des Sel (2010) 0.99
Drugs derived from phage display: from candidate identification to clinical practice. MAbs (2014) 0.91
Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem (2011) 0.88
Critical ligand binding reagent preparation/selection: when specificity depends on reagents. AAPS J (2007) 0.88
Accessing the human repertoire for broadly neutralizing HIV antibodies. MAbs (2011) 0.88
Rational conversion of affinity reagents into label-free sensors for Peptide motifs by designed allostery. ACS Chem Biol (2010) 0.85
Engineering anti-vascular endothelial growth factor single chain disulfide-stabilized antibody variable fragments (sc-dsFv) with phage-displayed sc-dsFv libraries. J Biol Chem (2010) 0.84
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules (2015) 0.82
Chaperone-assisted thermostability engineering of a soluble T cell receptor using phage display. Sci Rep (2013) 0.81
Fluorescent labeling of antibody fragments using split GFP. PLoS One (2011) 0.81
Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries. Int J Mol Sci (2012) 0.79
Targeting of phage particles towards endothelial cells by antibodies selected through a multi-parameter selection strategy. Sci Rep (2017) 0.79
Single-chain Fv phage display propensity exhibits strong positive correlation with overall expression levels. BMC Biotechnol (2008) 0.78
DeltaPhage--a novel helper phage for high-valence pIX phagemid display. Nucleic Acids Res (2012) 0.77
Construction and characterization of single-chain variable fragment antibody library derived from germline rearranged immunoglobulin variable genes. PLoS One (2011) 0.77
Optimal Neutralization of Centruroides noxius Venom Is Understood through a Structural Complex between Two Antibody Fragments and the Cn2 Toxin. J Biol Chem (2015) 0.77
Ligand-targeted theranostic nanomedicines against cancer. J Control Release (2016) 0.77
Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy. Int J Mol Sci (2016) 0.77
Distinct antibody species: structural differences creating therapeutic opportunities. Curr Opin Immunol (2016) 0.76
Degradation of C-terminal tag sequences on domain antibodies purified from E. coli supernatant. MAbs (2014) 0.76
An efficient method for variable region assembly in the construction of scFv phage display libraries using independent strand amplification. MAbs (2012) 0.76
Recent advances in the generation of human monoclonal antibody. Cytotechnology (2007) 0.76
Antibody engineering using phage display with a coiled-coil heterodimeric Fv antibody fragment. PLoS One (2011) 0.76
Ff-nano, short functionalized nanorods derived from Ff (f1, fd, or M13) filamentous bacteriophage. Front Microbiol (2015) 0.76
Apparent structural differences at the tetramerization region of erythroid and nonerythroid beta spectrin as discriminated by phage displayed scFvs. Protein Sci (2011) 0.76
Generation of “LYmph Node Derived Antibody Libraries” (LYNDAL) for selecting fully human antibody fragments with therapeutic potential. MAbs (2014) 0.76
Generation of high-affinity fully human anti-interleukin-8 antibodies from its cDNA by two-hybrid screening and affinity maturation in yeast. Protein Sci (2010) 0.75
Lactobacillus helveticus MIMLh5-specific antibodies for detection of S-layer protein in Grana Padano protected-designation-of-origin cheese. Appl Environ Microbiol (2013) 0.75
Engineered Autonomous Human Variable Domains. Curr Pharm Des (2016) 0.75
A nanobody:GFP bacterial platform that enables functional enzyme display and easy quantification of display capacity. Microb Cell Fact (2016) 0.75
Multivalent pIX phage display selects for distinct and improved antibody properties. Sci Rep (2016) 0.75
Specific Recognition of a Single-Stranded RNA Sequence by a Synthetic Antibody Fragment. J Mol Biol (2016) 0.75
The Molecular Engineering of an Anti-Idiotypic Antibody for Pharmacokinetic Analysis of a Fully Human Anti-Infective. PLoS One (2015) 0.75
Baculovirus display of functional antibody Fab fragments. Cytotechnology (2015) 0.75
The library of human miniantibodies in the phage display format: designing and testing. Dokl Biochem Biophys (2006) 0.75
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 4.43
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res (2002) 3.14
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol (2006) 2.66
Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids. PLoS One (2007) 2.28
A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res (2004) 2.00
Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine (2002) 1.69
Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res (2011) 1.62
Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis (2002) 1.61
A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol (2006) 1.59
Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets (2004) 1.48
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol (2007) 1.48
Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun (2009) 1.43
Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res (2005) 1.38
Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One (2009) 1.35
Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res (2003) 1.33
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol (2007) 1.32
Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods Mol Biol (2009) 1.32
Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS One (2010) 1.28
Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res (2006) 1.26
Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β. J Clin Invest (2011) 1.25
Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res (2004) 1.25
Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther (2007) 1.22
Phage versus phagemid libraries for generation of human monoclonal antibodies. J Mol Biol (2002) 1.18
Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol (2007) 1.11
A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol (2010) 1.10
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta (2002) 1.08
The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol (2002) 1.08
Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol (2007) 1.07
Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog (2005) 1.06
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biother Radiopharm (2005) 1.06
An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging (2010) 1.05
Towards proteome-wide production of monoclonal antibody by phage display. J Mol Biol (2002) 1.05
Using phage display to select antibodies recognizing post-translational modifications independently of sequence context. Mol Cell Proteomics (2006) 1.00
Yeast mating for combinatorial Fab library generation and surface display. FEBS Lett (2004) 0.99
Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. J Mol Med (Berl) (2007) 0.99
Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res (2008) 0.99
Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog (2005) 0.98
Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy. J Biol Chem (2007) 0.98
Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother (2007) 0.96
Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol (2009) 0.95
A novel assay for monitoring internalization of nanocarrier coupled antibodies. BMC Immunol (2006) 0.95
Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies. J Immunol Methods (2004) 0.94
Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res (2009) 0.93
Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Mol Cancer Ther (2012) 0.92
Tumor detection by imaging proteolytic activity. Cancer Res (2010) 0.92
Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release (2009) 0.92
Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. J Mol Med (Berl) (2009) 0.92
Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res (2008) 0.90
An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol (2012) 0.90
Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. J Mol Biol (2010) 0.89
Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther (2011) 0.89
Enzyme-amplified protein microarray and a fluidic renewable surface fluorescence immunoassay for botulinum neurotoxin detection using high-affinity recombinant antibodies. Anal Chim Acta (2006) 0.88
Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem (2011) 0.88
N-Terminal labeling of filamentous phage to create cancer marker imaging agents. ACS Nano (2012) 0.88
Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodies. Biosens Bioelectron (2009) 0.87
A functional dual-coated (FDC) microtiter plate method to replace the botulinum toxin LD50 test. Anal Biochem (2012) 0.87
Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. Biochem J (2013) 0.86
Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies. BMC Biochem (2011) 0.85
Renewable surface fluorescence sandwich immunoassay biosensor for rapid sensitive botulinum toxin detection in an automated fluidic format. Analyst (2009) 0.84
Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res (2010) 0.84
Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. Cancer Res (2010) 0.83
Simultaneous and sensitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays. Anal Biochem (2012) 0.82
Phage-display antibody detection of Chlamydia trachomatis-associated antigens. Microbiology (2002) 0.82
The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. Eur J Immunol (2002) 0.82
Rapid multiplexed flow cytometric assay for botulinum neurotoxin detection using an automated fluidic microbead-trapping flow cell for enhanced sensitivity. Anal Chem (2009) 0.81
RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin. Talanta (2013) 0.80
Development and Implementation of Checklists for Routine Anesthesia Care: A Proposal for Improving Patient Safety. Anesth Analg (2015) 0.79
Building and characterizing antibody-targeted lipidic nanotherapeutics. Methods Enzymol (2012) 0.79
Identification of target and function specific antibodies for effective drug delivery. Methods Mol Biol (2009) 0.79
Synergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes. Biotechnol Bioeng (2011) 0.79
Development of human single-chain antibodies against SARS-associated coronavirus. Intervirology (2008) 0.79
Use of a new functional dual coating (FDC) assay to measure low toxin levels in serum and food samples following an outbreak of human botulism. J Med Microbiol (2013) 0.78
Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins. Analyst (2014) 0.78
Identifying blood-brain-barrier selective single-chain antibody fragments. Biotechnol J (2014) 0.77
Discovery of internalizing antibodies to tumor antigens from phage libraries. Methods Enzymol (2012) 0.77
Selection and characterization of cell binding and internalizing phage antibodies. Arch Biochem Biophys (2012) 0.77
Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma (2012) 0.76
TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS. Am J Transl Res (2010) 0.76
Characterization of a single-chain intrabody directed against the human receptor tyrosine kinase Ron. J Immunol Methods (2004) 0.75
Predicting antigenic peptides suitable for the selection of phage antibodies. Hum Antibodies (2003) 0.75